Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Trial Results
Bristol Myers Squibb reports positive Phase 3 SCOUT-HCM results showing Camzyos efficacy and safety in adolescents with oHCM, achieving significant LVOT reduction with no new safety concerns.
Bristol Myers Squibb SCOUT-HCM Trial | 30/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy